Total Payments
$962,727
2024 Payments
$73,887
Companies
35
Transactions
1,063
Medicare Patients
4,486
Medicare Billing
$568,938
Payment Breakdown by Category
Other$545,997 (56.7%)
Consulting$224,964 (23.4%)
Travel$121,422 (12.6%)
Research$45,248 (4.7%)
Food & Beverage$24,773 (2.6%)
Education$264.41 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $542,372 | 211 | 56.3% |
| Consulting Fee | $224,964 | 62 | 23.4% |
| Travel and Lodging | $121,422 | 229 | 12.6% |
| Unspecified | $45,248 | 29 | 4.7% |
| Food and Beverage | $24,773 | 517 | 2.6% |
| Honoraria | $3,625 | 3 | 0.4% |
| Education | $264.41 | 11 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$917,479
1,034 transactions
Research
$45,248
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $287,609 | 205 | $0 (2023) |
| Novo Nordisk Inc | $245,613 | 277 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $157,012 | 142 | $0 (2019) |
| Lilly USA, LLC | $60,544 | 77 | $0 (2024) |
| Eli Lilly and Company | $43,999 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $39,853 | 51 | $0 (2021) |
| Abbott Laboratories | $38,695 | 99 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29,271 | 51 | $0 (2021) |
| Novo Nordisk AS | $23,451 | 13 | $0 (2019) |
| Janssen Global Services, LLC | $5,978 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $73,887 | 87 | Eli Lilly and Company ($24,089) |
| 2023 | $32,846 | 42 | Novo Nordisk Inc ($15,592) |
| 2022 | $16,920 | 11 | Eli Lilly and Company ($16,495) |
| 2021 | $2,003 | 12 | Abbott Laboratories ($988.77) |
| 2020 | $4,844 | 4 | SANOFI-AVENTIS U.S. LLC ($3,599) |
| 2019 | $287,463 | 214 | SANOFI-AVENTIS U.S. LLC ($107,276) |
| 2018 | $248,379 | 248 | SANOFI-AVENTIS U.S. LLC ($75,317) |
| 2017 | $296,385 | 445 | SANOFI-AVENTIS U.S. LLC ($94,714) |
All Payment Transactions
1,063 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Diabetes | ||||||
| 12/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,925.00 | General |
| Category: Diabetes | ||||||
| 12/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $127.00 | General |
| Category: Diabetes Care | ||||||
| 12/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Diabetes Care | ||||||
| 12/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Diabetes Care | ||||||
| 12/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $421.99 | General |
| 12/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $318.76 | General |
| 12/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $196.69 | General |
| 12/12/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $94.04 | General |
| Category: Diabetes Care | ||||||
| 12/11/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $185.69 | General |
| 12/01/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Diabetes Care | ||||||
| 12/01/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $12.06 | General |
| Category: Diabetes Care | ||||||
| 11/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $311.63 | General |
| Category: Diabetes Care | ||||||
| 11/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $251.59 | General |
| Category: Diabetes Care | ||||||
| 11/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $90.00 | General |
| Category: Diabetes Care | ||||||
| 10/29/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $86.75 | General |
| Category: Durable Pump | ||||||
| 10/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $45.94 | General |
| Category: Diabetes | ||||||
| 10/10/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Diabetes | ||||||
| 10/10/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,925.00 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $598.14 | General |
| 09/26/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Diabetes Care | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $10,274.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $15,150 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $11,777 | 2 |
| 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both Plus Mealtime Insulin in Patients With Typ | SANOFI-AVENTIS U.S. LLC | $2,526 | 3 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L) | SANOFI-AVENTIS U.S. LLC | $2,110 | 1 |
| Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM; | SANOFI-AVENTIS U.S. LLC | $2,070 | 1 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination vs Insulin Glargine in Patients with T2D (LixiLan-L) | SANOFI-AVENTIS U.S. LLC | $1,976 | 3 |
| A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three T | SANOFI-AVENTIS U.S. LLC | $1,363 | 2 |
| Efficacy and Safety of Insulin Glargine Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM;Efficacy and Safety of | SANOFI-AVENTIS U.S. LLC | $1,338 | 1 |
| A randomized, 30-week, active-controlled, open label, 2 treatment-arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine lixisenatide fixed ratio combination | SANOFI-AVENTIS U.S. LLC | $1,045 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | Eli Lilly and Company | $1,013 | 2 |
| Type 1 Diabetes Exchange Clinic Registry dataset | SANOFI-AVENTIS U.S. LLC | $927.50 | 2 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $865.30 | 1 |
| A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Na?ve Patients Initiating Insulin (Reach-Control) | SANOFI-AVENTIS U.S. LLC | $807.84 | 1 |
| 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both in Combination With Oral Antihyperglycemic | SANOFI-AVENTIS U.S. LLC | $719.94 | 1 |
| A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to "Standard of Care" Ins | SANOFI-AVENTIS U.S. LLC | $420.08 | 1 |
| EDITION 2 6-months | SANOFI-AVENTIS U.S. LLC | $349.69 | 1 |
| 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus? both in combination with oral antihyperglycem | SANOFI-AVENTIS U.S. LLC | $313.97 | 1 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes | SANOFI-AVENTIS U.S. LLC | $243.20 | 1 |
| REACH Control | SANOFI-AVENTIS U.S. LLC | $190.74 | 1 |
| A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiat | SANOFI-AVENTIS U.S. LLC | $42.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 671 | 4,250 | $326,324 | $111,586 |
| 2022 | 14 | 1,031 | 5,541 | $429,514 | $136,242 |
| 2021 | 14 | 1,534 | 7,885 | $482,547 | $173,453 |
| 2020 | 22 | 1,250 | 7,139 | $437,340 | $147,658 |
Total Patients
4,486
Total Services
24,815
Medicare Billing
$568,938
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 35 | 3,180 | $130,380 | $57,592 | 44.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 258 | 451 | $139,359 | $39,384 | 28.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 68 | 140 | $14,420 | $3,557 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 20 | $8,300 | $2,719 | 32.8% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2023 | 33 | 69 | $11,040 | $2,635 | 23.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 136 | 251 | $5,271 | $2,334 | 44.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 47 | 47 | $8,742 | $1,374 | 15.7% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 21 | 22 | $5,368 | $1,348 | 25.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 38 | 54 | $3,348 | $591.42 | 17.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 16 | 16 | $96.00 | $51.36 | 53.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 48 | 3,840 | $153,600 | $61,670 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 278 | 482 | $147,118 | $40,728 | 27.7% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2022 | 154 | 395 | $61,620 | $16,682 | 27.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 91 | 194 | $22,310 | $4,710 | 21.1% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 193 | 316 | $6,636 | $2,978 | 44.9% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 14 | 16 | $6,864 | $1,834 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 14 | $5,712 | $1,614 | 28.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 54 | 54 | $10,044 | $1,473 | 14.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 21 | $4,504 | $1,265 | 28.1% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 15 | 17 | $4,080 | $1,063 | 26.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 11 | 12 | $1,106 | $839.18 | 75.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 52 | 68 | $4,624 | $741.05 | 16.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 78 | 100 | $700.00 | $325.34 | 46.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 11 | 12 | $596.00 | $320.00 | 53.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 59 | 5,580 | $195,300 | $87,815 | 45.0% |
About Dr. Carol Wysham, MD
Dr. Carol Wysham, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Spokane, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457344541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carol Wysham, MD has received a total of $962,727 in payments from pharmaceutical and medical device companies, with $73,887 received in 2024. These payments were reported across 1,063 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($542,372).
As a Medicare-enrolled provider, Wysham has provided services to 4,486 Medicare beneficiaries, totaling 24,815 services with total Medicare billing of $568,938. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Spokane, WA
- Active Since 08/24/2005
- Last Updated 12/15/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1457344541
Products in Payments
- INVOKANA (Drug) $165,116
- TOUJEO (Drug) $127,347
- SOLIQUA (Drug) $84,795
- Tresiba (Drug) $80,391
- Ozempic (Drug) $65,358
- JARDIANCE (Drug) $48,502
- Victoza (Drug) $40,856
- SOLIQUA 100/33 (Drug) $35,706
- BYDUREON (Drug) $25,949
- NO PRODUCT DISCUSSED (Drug) $25,926
- Xultophy 100/3.6 (Drug) $22,334
- MOUNJARO (Drug) $19,037
- FARXIGA (Drug) $13,827
- FreeStyle Libre Pro (Device) $11,410
- FREESTYLE LIBRE 3 (Device) $10,080
- TOUJEO (Biological) $6,579
- AFREZZA (Drug) $5,973
- FreeStyle Lite system (Device) $5,403
- Dexcom CGM (Device) $5,385
- FreeStyle Freedom Lite system (Device) $4,878
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Spokane
Lynn Kohlmeier, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $493,965
Endocrinology, Diabetes & Metabolism $493,965
Harold Cathcart, Do, DO
Endocrinology, Diabetes & Metabolism — Payments: $89,976
Endocrinology, Diabetes & Metabolism $89,976
Mihaela Cosma, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $4,918
Endocrinology, Diabetes & Metabolism $4,918
Dr. Jeffrey Hartman, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $3,830
Endocrinology, Diabetes & Metabolism $3,830
Lisanne Laurier, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $591.64
Endocrinology, Diabetes & Metabolism $591.64
Maria Janout, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $175.57
Endocrinology, Diabetes & Metabolism $175.57